Evidence suggests that β-amyloid (Aβ) peptide triggers a pathogenic cascade leading to neuronal loss in Alzheimer's disease (AD). However, the causal link between Aβ and neuron death in vivo remains unclear since most animal models fail to recapitulate the dramatic cell loss observed in AD. We have recently developed transgenic mice that overexpress human APP and PS1 with five familial AD mutations (5XFAD mice) and exhibit robust neuron death. Here, we demonstrate that genetic deletion of the β-secretase (BACE1) not only abrogates Aβ generation and blocks amyloid deposition but also prevents neuron loss found in the cerebral cortex and subiculum, brain regions manifesting the most severe amyloidosis in 5XFAD mice. Importantly, BACE1 gene deletion also rescues memory deficits in 5XFAD mice. Our findings provide strong evidence that Aβ ultimately is responsible for neuron death in AD and validate the therapeutic potential of BACE1-inhibiting approaches for the treatment of AD.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia among the elderly population, but no treatments addressing the underlying cause of disease have been developed. One of the hallmarks of AD is extensive neuronal death in the brain, approaching 90% loss in certain regions such as entorhinal cortex and nucleus basalis (for review, see Morrison and Hof, 1997) . Although the precise mechanisms of AD and related cell loss and memory deficits are not fully determined, data support the hypothesis that amyloid-β (Aβ) peptides trigger a pathologic cascade ultimately leading to neuron death and cognitive impairment in AD (Hardy and Selkoe, 2002; LaFerla and Oddo, 2005; Selkoe and Schenk, 2003; Sisodia and St George-Hyslop, 2002; Turner et al., 2003) . Mutations in the genes for amyloid precursor protein (APP) and presenilins 1/2 (PS1/2) cause familial AD (FAD) and increase production of the 42-amino acid form of Aβ (Aβ42). Furthermore, Aβ kills neurons in culture (for review, see Yankner, 1996) , and Aβ also appears neurotoxic in vivo. For example, when directly injected into the brains of aged primates, fibrillar Aβ causes neuron death around the injection site (Geula et al., 1998) . However, the case for the role of Aβ in neuron death has been challenged because many APP transgenic mice that overproduce Aβ form amyloid plaques and develop memory deficits but do not lose significant numbers of neurons (Irizarry et al., 1997a; Irizarry et al., 1997b; for review, see McGowan et al., 2006) . Recently, new APP/PS1 transgenic mouse lines developed by our group and others show considerable neuron loss in the hippocampus (Casas et al., 2004; Schmitz et al., 2004) or the cortex and subiculum (Oakley et al., 2006) . These studies suggest that Aβ does kill neurons in vivo, although they cannot formally exclude the possibility that overexpression of APP and PS1 with multiple FAD mutations is the cause of neuron death in these mouse models.
β-Site APP-cleaving enzyme 1 (BACE1) has been identified as the β-secretase, the protease that initiates cleavage of APP to generate pathogenic Aβ peptides (Haniu et al., 2000; Hussain et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Yan et al., 1999) . As the rate-limiting enzyme for Aβ production, BACE1 is a prime therapeutic target for lowering cerebral Aβ levels in AD. 
